Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
Haozhou Tan, Yanmei Hu, Prakash D. Jadhav, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7561-7580
Open Access | Times Cited: 118

Showing 26-50 of 118 citing articles:

9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2
Kabita Pandey, Devin S. M. Lewis, Kyun Heo, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Exploring natural compounds and synthetic derivatives as potential inhibitors of SARS-CoV-2 PLpro: a computational approach with enzyme inhibition and cytotoxicity assessment
Shahkaar Aziz, Sana Khan, Alaa Karkashan, et al.
Journal of Biomolecular Structure and Dynamics (2025), pp. 1-21
Closed Access
Expanding the utilization of binding pockets proves to be effective for noncovalent small molecule inhibitors against SARS-CoV-2 Mpro
Qi Yang, Xupeng Huang, Hongbo Zhang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117497-117497
Closed Access
Research progress on critical viral protease inhibitors for coronaviruses and enteroviruses
Shulei Hu, Qiuyu Zhong, Xiong Xie, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130168-130168
Closed Access
Evaluating phytochemicals as SARS-CoV-2 papain-like protease inhibitors: a docking, ADMET and molecular dynamics investigation
Padmika Madushanka Wadanambi, Uthpali Mannapperuma, Nimanthi Jayathilaka
Chemical Papers (2025)
Closed Access
Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches
Qiang Shao, Muya Xiong, Jiameng Li, et al.
Chemical Science (2023) Vol. 14, Iss. 18, pp. 4681-4696
Open Access | Times Cited: 12
Silver N-heterocyclic carbene complexes are potent uncompetitive inhibitors of the papain-like protease with antiviral activity against SARS-CoV-2
María Gil‐Moles, Cillian O’Beirne, Igor V. Esarev, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 7, pp. 1260-1271
Open Access | Times Cited: 12
A Patent Review on SARS Coronavirus Papain‐Like Protease (PLpro) Inhibitors
C. S. Brian Chia, Siew Pheng Lim
ChemMedChem (2023) Vol. 18, Iss. 16
Open Access | Times Cited: 12
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
Ana C. Puhl, André S. Godoy, G.D. Noske, et al.
ACS Omega (2023) Vol. 8, Iss. 25, pp. 22603-22612
Open Access | Times Cited: 12
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
Yiying Xue, Husheng Mei, Yisa Chen, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 11
Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery
Xin Li, Yongcheng Song
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103832-103832
Open Access | Times Cited: 11
Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2
Miao Zheng, Bo Feng, Yumin Zhang, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 3286-3290
Open Access | Times Cited: 4
Systematic Studies on the Anti-SARS-CoV-2 Mechanisms of Tea Polyphenol-Related Natural Products
Chenwei Li, Tai‐Ling Chao, Chin-Lan Lai, et al.
ACS Omega (2024) Vol. 9, Iss. 22, pp. 23984-23997
Open Access | Times Cited: 4
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Yongzhi Lu, Qi Yang, Ting Ran, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Ensitrelvir as a potential treatment for COVID-19
Matthew W. McCarthy
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 1995-1998
Closed Access | Times Cited: 17
Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
Qian Wang, Guofeng Chen, Jian He, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8633-8633
Open Access | Times Cited: 10
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 10
A community effort in SARS‐CoV‐2 drug discovery
Johannes Schimunek, Philipp Seidl, Katarina Elez, et al.
Molecular Informatics (2023) Vol. 43, Iss. 1
Open Access | Times Cited: 9
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection
Lei Tian, Taotao Qiang, Xiuding Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115979-115979
Closed Access | Times Cited: 9
SARS-CoV-2 replication and drug discovery
Farah Nazir, Arnaud John Kombe Kombe, Zunera Khalid, et al.
Molecular and Cellular Probes (2024) Vol. 77, pp. 101973-101973
Open Access | Times Cited: 3
Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity
Angelo Oneto, Ghazl Al Hamwi, Laura Schäkel, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14986-15011
Closed Access | Times Cited: 3
COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way
Arpana Parihar, Shivani Malviya, Raju Khan, et al.
Bioscience Reports (2023) Vol. 43, Iss. 7
Open Access | Times Cited: 8
The Third CACHE Challenge – Finding Ligands Targeting the Macrodomain of SARS-CoV-2 NSP3 Using AI-inspired and Knowledge-Based Approaches.
Suneel Kumar B.V.S, Ophélie Rostaing, Mihai Burai Patrascu, et al.
(2024)
Open Access | Times Cited: 2
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Yongzhi Lu, Qi Yang, Ting Ran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Molecular docking-based virtual screening and computational investigations of biomolecules (curcumin analogs) as potential lead inhibitors for SARS-CoV-2 papain-like protease
Taufik Muhammad Fakih, Ritmaleni Ritmaleni, Rahadian Zainul, et al.
Pharmacia (2024) Vol. 71, pp. 1-19
Open Access | Times Cited: 2

Scroll to top